dm+d

Unassigned

New Medicines

Prostate cancer, castration-resistant - first-line in combination with abiraterone

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Small molecule inhibitor of Akt
The age-standardised incidence of prostate cancer in the UK in 2014 was 175 per 100,000 population [1].
Prostate cancer, castration-resistant - first-line in combination with abiraterone
Oral

Further information

Yes

Trial or other data

Jun 20In topline data, PIII IPATential150 hit one co-primary endpoint and missed the second. The drug showed a statistically significant improvement in radiological progression free survival (rPFS) in patients with metastatic castrate resistant prostate cancer, and who had tumours with PTEN loss. The drug did not meet the co-primary endpoint of rPFS in the overall study population [7].

Evidence based evaluations

Triple negative breast cancer - first-line

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Sep 20Development discontinued as trial failed to meet primary endpoint [8].

Category

Small molecule inhibitor of Akt
15% of patients with breast cancer have triple negative disease.
Triple negative breast cancer - first-line
Oral

Evidence based evaluations